EVALUATION OF THE COST EFFECTIVENESS OF THE TREATMENT OF MILD AND MODERATE ALZHEIMER'S DISEASE

被引：0
|
作者：
Langsch, L. R. [1 ]
机构：
[1] Univ Estado Rio de Janeiro, Sao Pedro Da Aldeia, Brazil
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2479
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM9
引用
收藏
页码：A860 / A860
页数：1
相关论文
共 50 条
  • [21] Treatment of institutionalized patients with Alzheimer's disease with quetiapine: A cost-effectiveness evaluation
    Getsios, D
    O'Brien, J
    Caro, JJ
    Pesa, J
    VALUE IN HEALTH, 2005, 8 (03) : 254 - 254
  • [22] Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
    Rive, B.
    Aarsland, D.
    Grishchenko, M.
    Cochran, J.
    Lamure, M.
    Toumi, M.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 27 (06) : 573 - 582
  • [23] Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease
    Seltzer, Ben
    CLINICAL INTERVENTIONS IN AGING, 2010, 5 : 1 - 6
  • [24] Switching, strategy with galantamine in the treatment of patients with mild to moderate Alzheimer's disease
    Hwang, T-Y.
    Ahn, I-S.
    Yun, J.
    Kim, S.
    Kim, D. K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 172 - 172
  • [25] The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer's Disease
    Ohnishi, Takashi
    Sakiyama, Yojiro
    Okuri, Yuichi
    Kimura, Yuji
    Sugiyama, Nami
    Saito, Takayuki
    Takahashi, Masayoshi
    Kobayashi, Takumi
    CURRENT ALZHEIMER RESEARCH, 2014, 11 (02) : 110 - 118
  • [26] ANALYSIS OF THE EFFECT OF GALANTAMINE IN THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE (AD)
    Moruzzi, E.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [27] Donepezil for the treatment of mild to moderate Alzheimer's disease in France: The economic implications
    Fagnani, F
    Lafuma, A
    Pechevis, M
    Rigaud, AS
    Traykov, L
    Seux, ML
    Forette, F
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 17 (1-2) : 5 - 13
  • [28] Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
    Pakdaman, Hossein
    Harandi, Ali Amini
    Hatamian, Hamidreza
    Tabatabae, Mojgan
    Kasmaei, Hosein Delavar
    Ghassemi, Amirhossein
    Gharagozli, Koroush
    Ashrafi, Farzad
    Naeini, Pardis Emami
    Tavakolian, Mehrnaz
    Shahin, Darush
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2015, 5 (01): : 96 - 106
  • [29] DEVELOPMENT OF A COST-EFFECTIVENESS ANALYSIS FRAMEWORK FOR MODELING TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT
    Roth, J. A.
    Cohen, J. T.
    Veenstra, D., I
    Chen, E.
    Jhuti, G. S.
    Neumann, P. J.
    Sullivan, S. D.
    VALUE IN HEALTH, 2015, 18 (07) : A698 - A699
  • [30] Sleep disturbance in mild to moderate Alzheimer's disease
    Moran, M
    Lynch, CA
    Walsh, C
    Coen, R
    Coakley, D
    Lawlor, BA
    SLEEP MEDICINE, 2005, 6 (04) : 347 - 352
12345